Alzheimer's Treatment Advancements: Disease-Modifying Therapies and Research Breakthroughs

Alzheimer's disease (AD) research has accelerated, yielding the first disease-modifying therapies and deeper mechanistic insights.

Recent Breakthroughs

  • Amyloid-targeting mAbs: Lecanemab (Leqembi) and donanemab (Kisunla) — FDA-approved (2023/2024) for early symptomatic AD (MCI/mild dementia). Modest cognitive/functional slowing (27–35% over 18 months) with amyloid plaque reduction. ARIA (edema/microhemorrhage) monitoring required.
  • Tau-targeting: Anti-tau antibodies, tau aggregation inhibitors, vaccines in trials.
  • Combination approaches: Amyloid + tau, amyloid + anti-inflammatory, metabolic targets.
  • Biomarker-driven trials: Blood-based p-tau217, GFAP, NfL enable earlier, cheaper screening.
  • Prevention trials: AHEAD 3-45 (lecanemab in preclinical), DIAN-TU (genetic AD).

Supportive Advances

  • Increased funding: NIH, philanthropy, industry.
  • Personalized medicine: APOE ε4 stratification; polygenic risk scores.
  • Lifestyle evidence: FINGER trial — multidomain intervention (diet, exercise, cognitive training, vascular control) reduces cognitive decline.
  • Early diagnosis: DSM-5-TR criteria; blood biomarkers entering clinical use.

Realistic Perspective

  • Current mAbs: modest benefit, significant cost/burden/risk; appropriate for carefully selected early-stage patients.
  • Not a cure; disease continues.
  • Equitable access remains a challenge.

Pipeline is robust; next decade may bring transformative combinations.

Illness - Related Articles